CMS Moves to Expose Medicare Advantage Networks and PBM Operations
The Centers for Medicare and Medicaid Services is moving to open two of the least transparent corners of managed care: Medicare Advantage provider directories and pharmacy benefit manager operations. A draft regulation issued on October 16 is designed to implement key provisions from healthcare legislation Congress passed this year, signaling a federal push to make insurance networks and drug pricing practices easier to scrutinize.
The policy focus is straightforward, even if the operational consequences are not. Medicare Advantage members rely on network directories to identify clinicians, specialists, and facilities they can actually use without surprise billing or access delays. When those directories are incomplete or outdated, patients can end up in plans that look broad on paper but behave very differently in practice. A rule aimed at directory accuracy therefore reaches beyond administration; it affects whether older adults can realistically connect with the care they think they purchased.
PBM transparency carries a different but equally consequential burden. Pharmacy benefit managers sit between insurers, drug manufacturers, and pharmacies, and their contracting and pricing arrangements have long been criticized for opacity. Bringing more visibility to those operations could make it easier to understand how drug access, formulary design, and patient cost exposure are shaped before a prescription ever reaches the pharmacy counter. In an environment where medication affordability remains a recurring source of nonadherence, even incremental clarity can alter how plans are judged by regulators, patients, and providers.
Why provider directory accuracy matters at the point of care
Directory errors are not merely clerical defects. They can delay specialist referrals, send patients to out-of-network clinicians, and create avoidable churn at the exact moment when beneficiaries need continuity. For older adults managing chronic disease, the practical stakes are high: inaccurate network information can interfere with follow-up for cardiology, oncology, endocrinology, behavioral health, or other ongoing needs. A Medicare Advantage plan that cannot reliably identify its clinicians has a trust problem before it has a utilization problem.
The pressure on directories has grown alongside the complexity of Medicare Advantage itself. Beneficiaries often choose plans based on the belief that a preferred primary care physician, specialist group, or hospital is available in network. If the directory lags behind reality, that choice becomes partly fictional. CMS’s emphasis on provider directory transparency suggests a desire to narrow the gap between what members see during enrollment and what they encounter when care is needed.
One sentence captures the clinical consequence: an inaccurate directory can function like a closed door.
PBM transparency and the drug access bottleneck
The PBM piece of the rule touches a different choke point in healthcare delivery. Patients rarely see the mechanisms that determine whether a drug is placed on a formulary, whether a preferred pharmacy is available, or what cost-sharing will accompany a prescription. Yet those decisions shape adherence as directly as any physician order. Greater transparency could make it easier to identify where pricing is being negotiated, how savings are distributed, and whether plan design favors lower out-of-pocket costs or simply shifts complexity onto patients.
The timing of this regulatory move also reflects a broader federal effort to document how healthcare dollars move through private payment systems. Medicare Advantage and PBMs both operate in spaces where the public sees the end result but not the machinery underneath. CMS’s draft rule appears aimed at shrinking that information gap. For policymakers, the appeal is obvious: clearer lines of sight make oversight easier. For providers, the benefit is more practical than philosophical, because better data can reduce referral friction, claims confusion, and the round of phone calls that often follows a bad network record or opaque pharmacy decision.
Patients with chronic disease stand to feel the difference first. Medication access failures and network misdirection do not usually present as headline events, but they accumulate into missed doses, delayed visits, and fragmented care. A transparency rule cannot fix every barrier, yet it can expose where those barriers are being built.
Congress, CMS, and the pressure to translate legislation into practice
Because the draft regulation is intended to implement recently passed legislation, the rule represents a classic federal translation problem: statutory intent must become enforceable operational standards. CMS now has to turn broad legislative goals into specific expectations for insurers and PBMs. That process often determines whether a policy becomes meaningful in day-to-day care or remains a compliance exercise buried in legal language.
The most immediate question is how much real-world change the rule can force once plans begin adjusting their systems. Provider directories are often large, dynamic datasets, and PBM arrangements are frequently embedded in contracts that are difficult for outsiders to interpret. If the final regulation pushes plans toward cleaner records and more readable disclosures, patients and clinicians may gain a more dependable map of the system they already navigate every day. If the rule stops at broad transparency language, the underlying opacity may persist in a different form.
For now, the significance of the draft is its direction. CMS is signaling that Medicare Advantage networks and PBM practices should no longer be treated as black boxes. The remaining test is whether the final rule produces information that is timely, usable, and specific enough to change access decisions at the bedside and at the pharmacy counter.